IMMUNODIAGNOSTICS  |  IMMUNOMONITORINGImmuQuad Biotech   ·   Contact@ImmuQuad.com
Let cancer cells have nowhere to hide

NGS-based measurable residual disease monitoring

Seq-MRD®—developed by ImmuQuad Biotech—uses next-generation sequencing of B-cell and T-cell receptor gene rearrangements to identify disease-associated clones and track them across treatment and follow-up.

Designed for professional use in lymphoid hematologic malignancies. Assay configuration depends on disease, sample type and intended use.

Illustration of identifying and longitudinally tracking a patient-specific immune receptor clone
2016Seq-MRD introduced by ImmuQuad as an NGS-based MRD solution.
2 stepsBaseline clonality identification followed by longitudinal MRD tracking.
6 lociTRB, TRG, IGH, incomplete IGH, IGK and IGL can be assessed.
Up to 10⁻⁶Potential tracking depth when sufficient sample input and assay requirements are met.
Why MRD matters

Remission does not always mean every malignant cell is gone

After treatment, a small number of disease-associated cells may remain below the detection range of routine morphology. Sensitive MRD monitoring can help clinicians assess response, refine risk evaluation and watch for molecular evidence of recurrence.

  • Measure treatment response beyond conventional morphology.
  • Monitor disease-associated sequences across clinically relevant time points.
  • Support longitudinal interpretation together with other clinical and laboratory findings.
Learn about MRD
Conceptual one-in-a-million sequence tracking illustration
A patient-specific strategy

Identify once. Track over time.

Seq-MRD begins with a high-disease-burden sample to identify disease-associated immune receptor sequences, then uses those sequences as molecular markers during therapy and follow-up.

Two-step Seq-MRD workflow
Technology advantages

Designed for sensitive, quantitative immune-receptor monitoring

VJ

Primer-bias control

Synthetic V–J-like controls can be used to optimize multiplex primer balance and improve library consistency.

Σ

Quantitative denominator

Internal reference materials support estimation of total nucleated-cell equivalents rather than reporting clone frequency alone.

6

Broad receptor coverage

Multiple BCR and TCR loci can be evaluated to improve the opportunity to find trackable disease-associated rearrangements.

SHM

Somatic hypermutation resilience

The assay strategy is designed to reduce loss of detection caused by somatic hypermutation in relevant B-cell malignancies.

UI

Clone interpretation

ImmuQuad’s reference repertoire database and Uniqueness Index contribute to interpretation of significant clones.

↗

Emerging-clone surveillance

Follow-up analysis can assess known markers while also screening for newly emerging clonal sequences.

Summary of the 2023 pediatric B-ALL clinical study
Peer-reviewed evidence

Clinical research using Seq-MRD technology

A 2023 Nature Communications study enrolled 430 pediatric B-ALL patients. At least one trackable immunoglobulin clonal rearrangement was identified in 399 patients (92.8%). The study evaluated IGH, IGK and IGL rearrangement-based MRD at the end of induction and consolidation.

A separate 2022 Bone Marrow Transplantation study evaluated NGS-MRD after CAR-T therapy in 20 patients with relapsed/refractory B-ALL who achieved complete remission.

Explore the evidence
Clinical and translational applications

Across major lymphoid hematologic malignancies

B-lineage leukemia

B-ALL and CLL/SLL applications may use immunoglobulin rearrangements as patient-specific molecular markers.

T-lineage leukemia

T-ALL and other T-lineage malignancies may be assessed through TCR rearrangement targets.

Lymphoma & myeloma

Selected B- or T-cell lymphomas and multiple myeloma may be suitable depending on sample quality and marker availability.

Discuss a Seq-MRD project with ImmuQuad

Clinical testing, translational research, clinical trials and biopharma collaborations.

Contact our team